Several different methods of measuring proliferation indices have been developed, including measurements of cellular DNA content (flow cytometry), S-phase incorporation of thymidine analogues into DNA (e.g., tritiated thymidine and 5'-bromodeoxyuridine), and immunostaining of cell cycle-restricted proteins (e.g., Ki-67 antigen and PCNA). Theoretical and practical problems with each method have made it difficult to compare absolute proliferation rates among cells of different lineages and degrees of malignancy. More recently, in situ hybridization (ISH) for histone 3 (H3) mRNA has been introduced. We used a double labeling method for comparing H3 mRNA expression and S-phase incorporation of 5'-bromodeoxyuridine (BrdU) to determine if H3 mRNA expression was tightly associated with S-phase in a variety of malignant and nontransformed cell types. In addition, labeling results were compared in methacarn-and Supported by grants CA-36250 (AMG and MDC) and KO8 DC-00035
Introduction
Accurate, reproducible cell proliferation analyses have been crucial in developing our present knowledge about normal and diseased tissue growth. For malignant tumors, loss of proliferation control is one of the major features of the malignant phenotype, and cell proliferation indices have proven useful as prognostic indicators of survival and response to therapies (1-6).
Many different methods have been used to identify and quantlfv proliferating cell populations in tissues. The present "gold standard" for determination of proliferative activity in tissues is the incorporation of thymidine analogues, such as [ 3H]-thymidine or 5-bromodeoxyuridine (BrdU), detected by autoradiography or immunocytochemistry, respectively (7,8). A major limitation to the use of thymidine analogues is the inability to perform retrospective studies. Although many cell cycle-restricted proteins, such as 78195.
formalin-fixed tissues to extend the potential usefulness of H3 ISH, using a postfixation technique for the alcohol-fixed specimens. As expected for a cumulative marker, variation was noted in the percentage of the BrdU-positive cells double labeled with H3 ISH (53-89%), depending on cell type and length of BrdU incubation. In contrast, the percentage of the H3 ISH-positive cell populations double labeled for BrdU was independent of the cell type or BrdU incubation time (mean 78%). Similarly, a consistent percentage of H3 ISH-positive cell populations was double labeled for BrdU in normal tissues (mean 97%). These fmdings support a wellconserved timing mechanism for H3 mRNA expression and DNA replication. We conclude that H3 ISH is an extremely accurate technique for assessment of S-phase cell prolifera- the Ki-67-defined antigen and proliferating cell nuclear antigen (PCNA), can now be identified by antibodies in fixed, embedded sections, none of these targets has proven to be ideal (9-13). Aside from problems of epitope masking or loss, detectable antigen levels can vary among different cell types, leading to spurious differences in calculated proliferation rates (1415). In addition, proliferation-related function can be regulated not only by protein levels but also by conformational changes not resolvable by immunocytochemistry (16) . In the case of malignant cells, dysregulation of cell cycle-restricted markers may also limit their usefulness as strict proliferation markers (14J7).
Analysis of cell cycle-associated mRNA species represents a new method for detecting proliferating cells that might combine the strengths of the present antibody-based methods. In addition, in contrast to the nuclear localization of most other proliferation markers, the cytoplasmic compartmentalization of mRNA would greatly facilitate the concomitant study of cell cycle-associated nuclear antigens such as the tumor suppressor gene product p53. Some histone mRNA species, including histone 3 (H3), have been shown by Northern blotting to be tightly linked to the S-phase of the cell cycle (18J9). Recently, it has been possible to demonstrate, by in situ hybridization (ISH), that H3 mRNA can be localized in a pat-22 1 222 GOWN, JIANG, MATLES, SKELLY, GOODPASTER, CASS, RESHATOF, SPAULDING, COLTRERA tern consonant with that of a proliferative marker in frozen as well as fixed, deparainized tissue sections (20) (21) (22) (23) . Using a double labeling methodology, we undertook this present study to further validate the relationship between H3 mRNA expression and S-phase, as defined by BrdU uptake in fixed, embedded tissues, and to see if H3 mRNA expression remained tightly associated with S-phase in malignant cells. In addition, labeling results were compared in methacarn-and formalin-fixed tissues to extend the potential usefulness of H3 ISH.
Materials and Methods
Cell Lines. Nontransformed and malignant human tumor cell lines representing different lineages and proliferation rates were employed. A204 (leiomyosarcoma) and HeLa (cervical carcinoma) were obtained from American Type Culture Collection (Rockville, Maryland). A malignant human melanoma cell line (H3606) was obtained from Dr. K.E. Hellsuom at Bristol Myers Squibb Research Institute-Seattle. For a nontransformed cell line, we used a low-passage nasal fibroblast cell line (NF1) harvested from nonmalignant nasal tissue specimens obtained at the University of Washington. All cell lines were grown at 37°C and 5% CO2 under nonconfluent conditions in Dulbecco's modified essential medium supplemented with 15% fetal calf serum (Gibco BRL; Grand Island, NY).
For production of BrdU-labeled cell pellets, BrdU (Sigma; St Louis, MO) was added to the culture media at a final concentration of 50 pg/ml and the cultures incubated at 37% for 30 min or 60 min. The cells were scraped from the plastic dishes with a rubber policeman, washed, and fixed in 4% neutral buffered formalin for 1 hr. The cells were then routinely processed. embedded in paraffin, and sectioned.
Animal Tissues. Adult female Sprague-Dawley rats were given an sc injection on the back with 100 mg BrdUlkg. After 30 min or 60 min, the animals were anesthetized and sacrificed. Representative portions of gut, spleen, and skin were fixed for 6 hr in 4% neutral buffered formalin or methacarn and routinely processed.
Immunocytochemistry. Methacarn-fixed and formalin-fixed sections were deparaffinized. rehydrated, and placed in a microwave oven (model 566.8878621; Sears, Chicago, IL) in 10 mM citric acid (pH 6.0) at 80% power for 5 min and were blocked in 0.3% H202 for 10 min. For BrdU detection, tissue sections were incubated for 1 hr at room temperature (RT) with anti-BrdU monoclonal antibody BU-1, a murine IgG (gift of Dr. Nick Gonchoroff, Rochester, MN; 1:5000 dilution). The sections were then rinsed in PBS and incubated for 30 min at RT in 1:lOO biotinylated rat-adsorbed horse anti-mouse IgG (H+ L) (Vector Laboratories; Burlingame, CA). Rinsed sections were then covered with standard avidin-biotin complex (ABC) (Vector) at RT for 30 min. The slides were developed in aminoethyl carbazole (AEC) substrate (Dako; Carpinteria, CA) for 10 min. Coverslips were applied with Dako Glycergel.
In Situ Hybridization. All reagents, including the H3 probe, were obtained from Dako. The H3 probe is a 550-base single-stranded, antisense, fluorescein-labeled DNA fragment that hybridizes to the entire coding region of the human histone H3 mRNA. It was used for in situ hybridization in the hybridization buffer supplied by the manufacturer. Briefly, for formalin-fixed specimens, deparaffinized, rehydrated slides were treated with 0.8% pepsin in 0.2 M HCI at 37% for 5-10 min and rinsed in dH2O several times. For methacarn-fixed tissues, after deparaffinization the sections were postfixed in neutral buffered formalin for 40 min and digested with 0.8% pepsin for 5-10 min for optimal labeling. Fluorescein-labeled H3 probe was applied to the sections and incubated overnight at 37°C. The slides were then washed in prewarmed Stringent wash buffer (Dako; 1:50) at 55'C for 15 min and rinsed in PBS. Sections were then incubated with alkaline phosphatase-conjugated anti-fluorescein antibodies at RT for 25 min. Development was performed in BCIP/NBT substrate for 2 hr. The slides were then dehydrated and coverslipped. Double Labeling. Pepsin-treated, formalin-fixed slides covered with H3 probe were incubated overnight at 37°C as indicated above. After development, the slides were microwaved at 80% power for 5 min in 10 mM citrate buffer, pH 6. Anti-BrdU antibody BU-1 (1:SOOO) was applied to sections for 1 hr at RT and then the imtnunostaining protocol was performed as outlined above.
Controls. Negative controls included deletion of the primary antibody or the in situ hybridization probe. As a control for signal loss in the double labeling experiments, adjacent single-labeled sections of the A204 cell line were also evaluated. A minimum of450 cells was counted and the labeling indices (LI%) for the single-labeled BrdU and H3 specimens were compared with the LI% for BrdU and H3 in the double-labeled preparations.
Labeling Index Calculation. Randomly selected fields were evaluated at high power for BrdU and H3 labeling. At least three separate slides were evaluated for each combination of cell blocks or tissues and immunocyto-chemicallISH labels. A minimum of 400 cells from three different highpowered ( x 40) fields was counted for each single-labeled and double-labeled preparation.
Results
Standard errors of the mean (SEM) are given in parenthesis in the tables. The Mann-Whitney statistical U-test was used to compare groups.
Cell Lines
Results of the cell line experiments are listed in Table 1 . Examples of immunostaining and in situ hybridization results are shown in Figure 1 . For both the malignant and the nontransformed cell line, similar percentages of the H3 ISH-positive cell populations were double labeled for BrdU (mean 78%; no statistically significant differences, p = 0.25).
For the BrdU-positive cell populations, more variation was noted in the percentage of double-labeled cells. The cell lines with the shortest in vitro doubling times, A204 and HeLa, demonstrated 53% and 66% double labeling, respectively, in the 60-min BrdU incubation experiments, whereas the slower doubling time cell lines, H3606 and NF-1, had means of 83% and 76%, respectively (Table  1) . To further explore the relationship between H3 ISH and BrdU double labeling, HeLa cells were incubated with BrdU for 30 min. The percentage of H3 ISH-positive cells double labeled for BrdU remained essentially the same (75%; p = 0.46), whereas the per- centage of BrdU-labeled cells double labeled for H3 ISH increased significantly (89%; p = 0.03) (Table 1) .
To account for potential signal loss in the double-labeled preparations, the LI% for both markers was compared in single-and double-labeled A204 cell line preparations. Counting an average of 450 cells in each preparation demonstrated no significant difference in LI% for either H3 ISH or BrdU (Table 2 ; p = 0.70 and p = 0.56, respectively).
Animal Tissues
In general, identical patterns of cell positivity were noted with both H3 ISH and BrdU immunocytochemistry ( Figures 1E-1H ). In rats that had been sacrificed 30 min after BrdU injection, near identity was found between H3 ISH and BrdU immunostaining, with over 93% of all labeled cells being double labeled for both markers (mean 97%) ( Figures 1E-1H ; Table 3 ). This relationship was consistent for the different tissue types examined. In comparing tissues from animals 30 min or 60 min post BrdU injection, no significant differences in the percentage of H3 ISH-positive cells double labeled for BrdU were observed in any of the tissues (p = 0.46). As previously seen in the HeLa cells, the percentage of BrdU-labeled cells double labeled for H3 ISH increased significantly in the 30-min post BrdU tissues compared with the 60-min post BrdU tissues (p = 0.03).
To analyze the postfixation technique for the detection of H3 ISH in methacarn-fixed specimens, comparison of the same tissue fixed in formalin or methacarn were made. No significant differences in double labeling percentages were noted ( Figures 1G and  1H ; Tables 3 and 4) (p value range = 0.09-0.71).
Discussion
An accurate method for evaluating cell proliferation in tissues and specimens fixed in different fixatives is of great interest to both clinical and basic science investigators. In addition to its use as an experimental tool, cell cycle information is increasingly used in Table 3 . Formalin-fixed rat tissuej predicting the "biological behavior" of many human tumors and as a method of predicting response to radiotherapy and chemotherapy regimens (2,24,2 5). Several different methods of measuring labeling indices (LI%; a measure of the proliferating cell percentage in a tumor cell population) have been developed over the years. These can be roughly categorized as measurements of cellular DNA content (flow cytometry), S-phase incorporation of thymidine analogues into the DNA (e.g., [3H]-thymidine and >-bromodeoxyuridine [BrdU]), immunostaining of cell cycle-restricted proteins (e.g., the Ki-67 antigen and PCNA), and in situ hybridization of cell cycle-associated mRNA species (e.g.. histones). Each method has its strengths and weaknesses.
Cell cycle studies have led to the identification of a number of proteins whose expression is restricted to portions of the active cell cycle (3. [26] [27] [28] [29] [30] [31] [32] [33] . The two proteins that have arguably found the most application to the study of human tumors are the Ki-67 antigen and PCNA (11,34). The original Ki-67 antibody, used in frozen sections, and the more recently introduced MIBl antibody developed for formalin-fixed specimens, detect an as yet undefined 345-395 KD protein complex (35, 36) . The antigen is detectable during all non-Go phases of the cycle, although the degree of G1 expression varies in different cell types (9). Correlation between S-phase indices and the number of cells immunostairied by antibody Ki-67 varies among different cell types and between malignant cell types and their nonmalignant counterparts (37) (38) (39) . PCNA, a subunit of DNA polymerase delta, was originally described as a late GI-, S-, and early Gpphase marker on the basis of work performed on lymphocytes (11) . Further studies of PCNA have demonstrated that the detectable levels of PCNA can vary significantly depending on cell type, malignant vs nontransformed state, and differential fixation characteristics that vary with cell cycleassociated PCNA conformation changes (14) (15) (16) (17) 40) .
Detection of thymidine analogues incorporated into cellular DNA has proven to be tightly associated with S-phase in the cell cycle for diverse cell types, both malignant and nontransformed. Although in selected studies terminal cancer patients have been given [ iH]-thymidine or BrdU, this is not a technique that can be employed routinely because these agents may be teratogenic and the long-term effects of BrdU incorporation into genomic DNA are poorly understood (41 the need for diffusion and uptake of the thymidine analogue (42, 43) . In addition, BrdU, with its bulky bromine atom, can interfere with normal gene expression, which may affect the phenotype or survival of the labeled cells (41). In situ hybridization localization of histone mRNA appears to avoid most of the thymidine analogue-associated methodological problems. In addition, in contrast to the other tissue-based markers, it has the unique property of cytoplasmic staining. Previous studies have demonstrated the use of H3 ISH as a reliable proliferation marker in a number of different tissue types in frozen tissue and, more recently, in formalinfixed tissues (20) (21) (22) (23) . We have extended these studies by performing a series of in vitro and in vivo studies to document the S-phase restriction of immunocytochemically detectable H3 ISH and to validate its use in tissue sections using a double labeling methodology.
Our results demonstrate a consistent relationship between H3 ISH positivity and S-phase as defined by BrdU incorporation. This relationship held true for cells of differing lineage, for malignant vs nontransformed cells in vitro, and for ddferent tissue types in vivo. The variation in the percentage of BrdU-positive cells that were also positive for H3 ISH is due to the different natures of the two markers. BrdU positivity is cumulative, whereas H3 ISH positivity is transient ( Figure 2 ). If H3 mRNA is consistently expressed just before entry into S-phase, the percentage of H3 ISH-positive cells that were also BrdU-positive (the overlapping region in Figure 2 ) would be expected to remain consistent for different cell types. This proved to be the case ( Table 1) . On the other hand, shortening the BrdU incubation time in vitro would be expected to increase the percentage of BrdU-positive cells that were also H3 ISH-positive, while leaving the converse relationship unchanged. This also proved to be true.
In analogous fashion, the rat tissue results demonstrated tightly coupled H3 expression in different tissue types. The higher percentage of double-labeled cells for both markers in the in vivo setting compared with the in vitro setting may be due to at least two factors. First, in vitro the BrdU is distributed immediately to all cells in monolayer culture, whereas in vivo the time needed for significant absorption effectively shortens the true exposure time to BrdU. Such an effect was demonstrated in the 60-min and 30-min HeLa experiments, in which the percentage of BrdU-labeled cells double labeled for H3 ISH increased from 66% to 89%, respectively (Table 1) Third, detectable expression of H3 mRNA may vary slightly among species, which could affect direct interspecies comparison of the in vitro (human cell lines) and the in vivo (rat tissues) results. Because alcohol-based fixatives such as methacarn do not crosslink proteins, many antigens are better preserved in the alcoholbased fixatives than in formalin (44) . At the same time formalin can better retain smaller proteins. This has led to the common use of both fixative types in immunocytochemical studies. By using a postfixation technique, we have been able to demonstrate that H3 ISH can be employed in both methacarn-and formalin-fixed tissues without the fixation-induced problems affecting PCNA or the Ki-67 antigen. The invariance of H3 ISH as a function of fixation should markedly increase its utility in cell proliferation studies, in both human and animal tissues. Nevertheless, it should be noted that H3 ISH is not without its own potential limitations as a technique outside the research setting. Degradation of mRNA is a theoretical problem in tissues in which a significant time interval elapses between tissue removal and immersion in fixative. 
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